Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study

<div>In one demonstrative case of the IVR group, the regression of the subretinal fluid after two consecutive monthly IVR administrations is clearly seen in a comparison of foveal OCT scans.</div>

Journal of Ophthalmology

fig4

Figure 4

Figure 4: Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study 

Figure 4 | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study 